SHCBP1 promotes cisplatin resistance and progression of LSCC through POU2F1-mediated transcriptional activation.

Mian Dai; Gang Qin; Yundan Bai

doi:10.14670/hh-25-127

July 20, 2026

SHCBP1 promotes cisplatin resistance and progression of LSCC through POU2F1-mediated transcriptional activation.

View at Publisher

Ask AI

Bookmark

Share

Key Points

This research aims to explore the role of SHCBP1 in affecting cisplatin resistance and tumor progression in LSCC.
Knockdown of SHCBP1 was performed to assess its impact on tumor growth and metastasis.
Cisplatin sensitivity was evaluated after SHCBP1 knockdown.
SHCBP1 knockdown suppressed tumor growth and metastasis.
Increased cisplatin sensitivity was observed following SHCBP1 knockdown, indicating its role in cisplatin resistance.

Implication

Knockdown of SHCBP1 increases cisplatin sensitivity in LSCC, suggesting a potential therapeutic target.

Abstract

experiments further confirmed that SHCBP1 knockdown suppressed tumor growth and metastasis and increased cisplatin sensitivity. Overall, SHCBP1 contributes to LSCC cisplatin resistance and progression by promoting POU2F1-mediated transcriptional activation.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Dai et al. (2026) studied this question.

synapsesocial.com/papers/6a605f464163e025518d8976 https://doi.org/10.14670/hh-25-127

View at Publisher

Ask AI

Bookmark

Share

SHCBP1 promotes cisplatin resistance and progression of LSCC through POU2F1-mediated transcriptional activation.

Key Points

Implication

Abstract

Discussion

Cite This Study

SHCBP1 promotes cisplatin resistance and progression of LSCC through POU2F1-mediated transcriptional activation.

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading